4D Molecular Therapeutics Inc. (FDMT): Price and Financial Metrics

4D Molecular Therapeutics Inc. (FDMT): $23.37

-0.40 (-1.68%)

POWR Rating

Component Grades













Add FDMT to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where FDMT ranks best; there it ranks ahead of 66.38% of US stocks.
  • The strongest trend for FDMT is in Momentum, which has been heading up over the past 179 days.
  • FDMT's current lowest rank is in the Stability metric (where it is better than 8.1% of US stocks).

FDMT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for FDMT is 0.01 -- better than only 8.1% of US stocks.
  • With a price/sales ratio of 390.25, 4D MOLECULAR THERAPEUTICS INC has a higher such ratio than 99.09% of stocks in our set.
  • Revenue growth over the past 12 months for 4D MOLECULAR THERAPEUTICS INC comes in at -88.37%, a number that bests just 1.39% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to 4D MOLECULAR THERAPEUTICS INC, a group of peers worth examining would be CYCN, DTIL, RARE, EDIT, and ONCT.
  • To dig deeper into the stock's financial statements, go to FDMT's page on browse-edgar?action=getcompany&CIK=0001650648.

FDMT Valuation Summary

  • In comparison to the median Healthcare stock, FDMT's price/sales ratio is 18680% higher, now standing at 375.6.
  • Over the past 24 months, FDMT's price/sales ratio has gone up 317.5.

Below are key valuation metrics over time for FDMT.

Stock Date P/S P/B P/E EV/EBIT
FDMT 2022-11-25 375.6 2.9 -7.0 -6.2
FDMT 2022-11-23 381.9 3.0 -7.2 -6.3
FDMT 2022-11-22 385.8 3.0 -7.2 -6.4
FDMT 2022-11-21 342.8 2.7 -6.4 -5.6
FDMT 2022-11-18 361.0 2.8 -6.8 -5.9
FDMT 2022-11-17 367.8 2.9 -6.9 -6.0

FDMT Price Target

For more insight on analysts targets of FDMT, see our FDMT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $50.00 Average Broker Recommendation 1.5 (Moderate Buy)

FDMT Stock Price Chart Interactive Chart >

Price chart for FDMT

FDMT Price/Volume Stats

Current price $23.37 52-week high $24.82
Prev. close $23.77 52-week low $5.32
Day low $23.20 Volume 269,700
Day high $24.25 Avg. volume 303,084
50-day MA $11.02 Dividend yield N/A
200-day MA $10.73 Market Cap 757.00M

4D Molecular Therapeutics Inc. (FDMT) Company Bio

4D Molecular Therapeutics is a biotechnology company. The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

FDMT Latest News Stream

Event/Time News Detail
Loading, please wait...

FDMT Latest Social Stream

Loading social stream, please wait...

View Full FDMT Social Stream

Latest FDMT News From Around the Web

Below are the latest news stories about 4D MOLECULAR THERAPEUTICS INC that investors may wish to consider to help them evaluate FDMT as an investment opportunity.

4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference

EMERYVILLE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that David Kirn, M.D., Co-Founder and Chief Executive Officer of 4DMT, will participate in a fireside chat at the Evercore ISI HealthCONx 2022 Conference. The fireside chat will take place on Wednesday, November 30, 2022 at 3:55 p.m. ET. A live audio webcast of the fireside cha

Yahoo | November 21, 2022

2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street

If your answer's yes, the biotech industry has you covered. Last week, two biotech companies independently announced some surprisingly good news that got the attention of investment banks on Wall Street. Ardelyx (NASDAQ: ARDX) is a commercial-stage biotech that markets a drug called Ibsrela for irritable bowel syndrome.

Yahoo | November 20, 2022

4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why

4D Molecular's (FDMT) progress with the development of its pipeline candidates in cystic fibrosis and wet AMD indications have been significant catalysts for the stock.

Yahoo | November 17, 2022

4D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial

4D Molecular Therapeutics Inc (NASDAQ: FDMT) announced interim clinical data from cohort 1 of the Phase 1/2 trial of intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD). 4D-150 was safe and well tolerated, with no serious adverse events or dose-limiting toxicities reported. No clinically significant intraocular inflammation, endophthalmitis, retinal vasculitis, retinal artery occlusion, choroidal effusions, and hypotony were reported to date. Also see: 4D Molecular Shares Fall

Yahoo | November 14, 2022

4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)

Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high need patients who in the 12 months preceding trial enrollment had a mean annualized anti-VEGF injection rate of ~11Following intravitreal 4D-150, Cohort 1 patients’ annualized anti-VEGF injection rate was reduced by 96.7%80% of Cohort 1 patients had not received any supplemental aflibercept injections for up to ~10 months after 4D-150 dosingCohort 1 safety and tolerability of 4D-150

Yahoo | November 14, 2022

Read More 'FDMT' Stories Here

FDMT Price Returns

1-mo 169.86%
3-mo 190.67%
6-mo 203.90%
1-year 1.61%
3-year N/A
5-year N/A
YTD 6.52%
2021 -47.07%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6688 seconds.